The lack of strong and specific tracer accumulation in the tumors led us to hypothesize that IL-2 secreted by RT-induced effector cells may compete with therapeutic IL-2c (and the 64Cu-NOTA-IL-2c tracer) for binding to CD122/γc receptors in the tumor microenvironment. The gene discussed is IL2RB; the disease is neoplasm.